SNAP-8 dosage chart
10 mg Vial (Topical)
SNAP-8 dosage is best expressed as the concentration of active acetyl octapeptide-3 in a finished topical research formulation. Human research has evaluated SNAP-8 in creams, multi-peptide serums, and purpose-built dissolving microneedle patches. The calculator below converts a 10 mg vial into actual active-peptide concentrations for topical cream, gel, or serum research.
- Format
- Topical research formulation (cream, gel, serum, or microneedle patch) — not injected.
- Active concentration
- The widely quoted 3% to 10% use level refers to a supplier solution containing about 0.05% SNAP-8. It equals roughly 0.0015% to 0.005% active peptide in the finished formula, not 3% to 10% pure peptide.
Dosing schedule
| Final Batch | Active Peptide | Active % w/w | ppm | Research Context |
|---|---|---|---|---|
| 30 g | 10 mg | 0.0333% w/w | 333 ppm | About 6.7 times the upper developer reference |
| 50 g | 10 mg | 0.0200% w/w | 200 ppm | 4 times the upper developer reference |
| 100 g | 10 mg | 0.0100% w/w | 100 ppm | 2 times the upper developer reference |
| 200 g | 10 mg | 0.0050% w/w | 50 ppm | Matches 10% of the nominal 0.05% supplier solution |
| 333.3 g | 10 mg | 0.0030% w/w | 30 ppm | Mid-range calculation |
| 666.7 g | 10 mg | 0.0015% w/w | 15 ppm | Matches 3% of the nominal 0.05% supplier solution |
Dosing schedule
| Final Batch | 0.0015% Active | 0.0030% Active | 0.0050% Active |
|---|---|---|---|
| 30 g | 0.45 mg | 0.90 mg | 1.50 mg |
| 50 g | 0.75 mg | 1.50 mg | 2.50 mg |
| 100 g | 1.50 mg | 3.00 mg | 5.00 mg |
| 200 g | 3.00 mg | 6.00 mg | 10.00 mg |
Dosing schedule
| Final Batch | Stock for 0.0015% | Stock for 0.0030% | Stock for 0.0050% |
|---|---|---|---|
| 30 g | 0.45 mL | 0.90 mL | 1.50 mL |
| 50 g | 0.75 mL | 1.50 mL | 2.50 mL |
| 100 g | 1.50 mL | 3.00 mL | 5.00 mL |
Dosing schedule
| Trade Solution | Peptide in Stock | Final Active % | Equivalent ppm |
|---|---|---|---|
| 3% | 0.05% | 0.0015% | 15 ppm |
| 6% | 0.05% | 0.0030% | 30 ppm |
| 10% | 0.05% | 0.0050% | 50 ppm |
Dosing schedule
| Study | Formulation | Schedule | Design Context | Evidence Limit |
|---|---|---|---|---|
| Lipotec developer panel | Cream with 10% of a nominal 0.05% SNAP-8 solution, equal to about 0.005% active peptide | Twice daily around the eye area for 28 days | 17 women; silicone replicas and profilometry; about 35% mean and 63% maximum wrinkle-depth reduction reported | Manufacturer-reported, not an independent peer-reviewed trial |
| Shin et al. (2024) | 350 micrometer dissolving patch with 0.03% SNAP-8, 5% AA2G, 4% cyclic LPA, and 90% HA | Overnight nightly through day 14, then every third day through day 28 | 24 enrolled and 21 completed a split-face active-versus-placebo comparison | Combination device; SNAP-8’s independent contribution cannot be isolated |
| Avcil et al. (2020) | HA microneedle patch with SNAP-8, other peptides, adenosine, and seaweed extracts | 12-week study | Fine lines, hydration, dermal density, thickness, and tolerability measures | Multi-active product; SNAP-8 concentration was not disclosed in the abstract |
| Draelos et al. (2016) | Multi-peptide serum containing SNAP-8 within a supporting skincare regimen | Morning and evening for 12 weeks after a 2-week washout | 29 women; investigator grading and participant questionnaires | Open label, no control, multiple peptides and supporting products |
| Moy et al. (2023) | Proprietary multi-peptide facial serum containing acetyl octapeptide-3 | Twice daily for 12 weeks | 31 women completed dermatologist grading, imaging, hydration, and questionnaires | Uncontrolled, multi-ingredient, and company funded |
SNAP-8 Dosage Chart for a 10 mg Vial
SNAP-8 dosage is best expressed as the concentration of active acetyl octapeptide-3 in a finished topical research formulation. Human research has evaluated SNAP-8 in creams, multi-peptide serums, and purpose-built dissolving microneedle patches. The calculator below converts a 10 mg vial into actual active-peptide concentrations for topical cream, gel, or serum research.
The widely quoted 3% to 10% use level refers to a supplier solution containing about 0.05% SNAP-8. It equals roughly 0.0015% to 0.005% active peptide in the finished formula, not 3% to 10% pure peptide.
Research context: For identity, mechanisms, human findings, limitations, and safety, read SNAP-8 Peptide: Benefits, Uses, Side Effects, Dosage, and Research.
- Best documented conventional cream reference: About 0.005% active SNAP-8, equal to 50 ppm.
- Developer reference range: About 0.0015% to 0.005% active peptide in the finished topical formula.
- Whole 10 mg vial at 0.005%: 200 g final batch weight.
- 50 g batch at 0.005%: 2.5 mg active peptide.
- Human schedule context: Twice-daily cream application for 28 days in manufacturer testing.
Dosing & Topical Formulation Guide
Active-peptide concentration math for a SNAP-8 10 mg vial
Whole 10 mg Vial Concentration Calculator
These rows show the mathematical concentration produced when the complete 10 mg vial is distributed through a measured final batch weight. The 200 g to 666.7 g rows span the developer’s finished-active reference range. Smaller batches produce higher concentrations.
Formula: Active percent w/w = peptide mg divided by final batch grams divided by 10. Parts per million = peptide mg divided by final batch grams multiplied by 1,000.
Small-Batch SNAP-8 Research Calculations
A typical 30 g or 50 g topical batch requires a measured portion of the vial to match the 0.0015% to 0.005% active reference range.
Formula: Peptide mg needed = target percent multiplied by final batch grams multiplied by 10.
Worked 1 mg/mL Stock Measurement Example
If a validated formulation plan uses the complete 10 mg vial in a measured 10.0 mL final stock volume, the nominal stock concentration is 1 mg/mL. Each 1.0 mL contains 1.0 mg SNAP-8. The stock must use a compatible vehicle, and the transferred amount becomes part of the final batch.
Important: This is measurement math, not a shelf-life claim. A base must accept the added aqueous phase without losing homogeneity or preservation. An analytical standard remained stable for 96 hours at 4 degrees C, but this does not validate a multiweek topical stock or cream.
How to Read the 3% to 10% SNAP-8 Range
The ingredient developer supplied SNAP-8 as a preserved aqueous blend containing approximately 0.05% acetyl octapeptide-3. Adding 3% to 10% of that solution gives 0.0015% to 0.005% actual peptide in the final product. A raw 10 mg vial and a preserved commercial premix are not operationally interchangeable.
Concentration math does not validate homogeneity, preservation, pH, compatibility, skin delivery, or shelf life. Those controls belong to the finished formulation.
Human SNAP-8 Research Formulations
Human evidence is topical or device-assisted. Conventional cream data come from ingredient-developer testing. Peer-reviewed studies used multi-active serums or dissolving microneedle patches, so their outcomes cannot be assigned to SNAP-8 alone.
SNAP-8 Topical Research Protocol Overview
- Developer active reference: Approximately 0.0015% to 0.005% active SNAP-8.
- Best documented conventional cream example: Approximately 0.005% active peptide.
- Application context: Twice daily around the eye area for 28 days in manufacturer testing.
- Academic serum context: Morning and evening or twice-daily use for 12 weeks in multi-ingredient studies.
- Patch context: Overnight nightly through day 14, then every third day through day 28 in a manufactured multi-active patch.
- Follow the vial supplier’s lot-specific storage documentation before formulation.
- Store the finished batch according to its validated base, preservative, pH, container, and stability plan.
- Do not transfer the trade solution’s published shelf life to a raw-vial formulation.
- An analytical standard remained stable for 96 hours at 4 degrees C, but that does not establish cosmetic-product shelf life.
Topical Preparation Planning
- Confirm active mass: Adjust the nominal 10 mg amount if the lot assay requires it.
- Select the research concentration: Keep the percentage attached to its source, vehicle, route, and schedule.
- Calculate peptide mass: Use the small-batch table for the selected final weight.
- Define the stock method: If the mass is below the balance’s reliable range, use an accurately quantified stock in a compatible vehicle under a validated plan.
- Transfer and mix: Include the complete measured stock in the final batch and use a validated method for uniform dispersion.
- Verify the batch: Record final weight, pH, appearance, packaging, dispensing amount, preservation controls, and testing.
- Label the study unit: Include concentration, batch ID, date, storage, and observation schedule.
- 10 mg in 200 g: 0.005% w/w or 50 ppm.
- 10 mg in 333.3 g: 0.003% w/w or 30 ppm.
- 10 mg in 666.7 g: 0.0015% w/w or 15 ppm.
- 50 g batch at 0.005%: 2.5 mg active peptide.
Read SNAP-8 Concentration Labels Carefully
Raw peptide concentration and supplier solution concentration describe different measurements. A formula containing a percentage of a premixed supplier solution should also state the calculated acetyl octapeptide-3 concentration in the finished batch.
How SNAP-8 Is Proposed to Work
SNAP-8 is acetyl octapeptide-3, an eight-amino-acid peptide modeled on part of SNAP-25. Its sequence is Ac-EEMQRRAD-NH2. The proposed cosmetic mechanism is interference with SNARE-complex assembly and calcium-dependent exocytosis. Direct SNAP-8 mechanism data are primarily developer-generated, so biological plausibility is not equivalent to proof of clinical muscle relaxation.
SNAP-8 is distinct from acetyl hexapeptide-8, also called Argireline. Argireline studies are related-peptide background, not direct SNAP-8 evidence.
Research Outcomes and Tolerability
- Wrinkle measurements: Studies used silicone replicas, profilometry, three-dimensional imaging, or investigator grading.
- Combination patch: Shin and colleagues reported improvements in selected wrinkle and skin-quality measures versus an HA-only patch, with no adverse effects reported during 28 days.
- Multi-active patch: Avcil and colleagues reported product-level changes in fine lines, hydration, density, and thickness, with excellent tolerability.
- Serum studies: Multi-ingredient studies reported selected appearance and hydration improvements, but the effect of SNAP-8 cannot be isolated.
- Formulation safety: Tolerability of a commercial formula or manufactured patch does not establish preservation, uniformity, or safety of a new raw-vial formulation.
Study Design and Tracking
- Define target area, measured amount, frequency, duration, and primary endpoint before the first observation.
- Use consistent lighting, camera position, facial expression, and time of day for images.
- Keep other skincare products and cosmetic procedures consistent or document each change.
- Record dispensing mass or volume so each application is reproducible.
- Track redness, itching, burning, swelling, dryness, eye exposure, pH drift, and product separation.
Topical Application and Measurement Controls
- Measure the dispensed amount: Use a calibrated pump, positive-displacement tool, or before-and-after container weight.
- Keep the target area consistent: Apply to the predefined external skin area and prevent direct eye or mucosal contact.
- Control the vehicle: Record the base formula because it affects spread, stability, preservation, and delivery.
- Do not equate delivery systems: A 0.03% dissolving microneedle patch is not equivalent to a 0.03% intact-skin cream.
SNAP-8 Dosage FAQ
For topical research, dosage is a finished concentration. A complete 10 mg vial produces 0.005% active SNAP-8 in a final 200 g batch. A 50 g batch at the same concentration uses 2.5 mg.
No. In developer materials, 10% refers to a nominal 0.05% supplier solution. The finished active concentration is about 0.005%, equal to 50 ppm.
The best documented example used about 0.005% active SNAP-8 twice daily for 28 days in a small manufacturer panel. It is a formulation reference, not an independently replicated treatment standard.
SNAP-8 dosage FAQs
How do you reconstitute a 10 mg Vial (Topical) vial of SNAP-8?
Add bacteriostatic water slowly down the inside wall of the 10 mg Vial (Topical) SNAP-8 vial, swirl gently until clear, and use the reconstitution calculator to convert your chosen water volume into syringe units.
What concentration does reconstituted SNAP-8 end up at?
Active concentration: The widely quoted 3% to 10% use level refers to a supplier solution containing about 0.05% SNAP-8. It equals roughly 0.0015% to 0.005% active peptide in the finished formula, not 3% to 10% pure peptide.. On any insulin syringe 1 unit = 0.01 mL, so unit counts convert directly across brands.
What does the SNAP-8 dosing schedule look like?
30 g — 10 mg — 0.0333% w/w — 333 ppm — About 6.7 times the upper developer reference; 50 g — 10 mg — 0.0200% w/w — 200 ppm — 4 times the upper developer reference; 100 g — 10 mg — 0.0100% w/w — 100 ppm — 2 times the upper developer reference; 200 g — 10 mg — 0.0050% w/w — 50 ppm — Matches 10% of the nominal 0.05% supplier solution. The full table above lists every step with matching syringe units.
How should reconstituted SNAP-8 be stored?
Once mixed, SNAP-8 is kept refrigerated at roughly 2–8 °C, protected from light, and never frozen. Unmixed lyophilised powder is the more stable form and is only reconstituted when it is needed.
How many insulin syringe units equal a SNAP-8 dose?
Units depend on the water volume you used. Divide your target dose by the vial concentration to get millilitres, then multiply by 100 — 1 unit on a U-100 insulin syringe is 0.01 mL. The Spartan Peptides reconstitution calculator does this conversion for you.
Is SNAP-8 approved for human use?
No. SNAP-8 is sold and referenced strictly as a research chemical. Nothing on this page is medical advice and the material is not for human consumption.
Educational and research information only. Not medical advice, not for human consumption. Values are reference figures — always verify your own math with the reconstitution calculator.
On any insulin syringe, 1 unit = 0.01 mL, so unit counts above hold across brands.